Clinical Trials
Idera completes patient enrollment in Phase 2 trial of IMO-3100
Idera Pharmaceuticals has concluded enrolling patients in double-blind, placebo-controlled Phase 2 trial assessing IMO-3100 in psoriasis patients. The study randomized 44 patients suffering from moderate to severe plaque psoriasis with IMO-3100 at 0.16mg/kg or...
Clinical Trials
Novavax pandemic influenza vaccine meets endpoints in two Phase 1 trials
Novavax A/H5N1 avian influenza vaccine candidate has met safety and immunogenicity endpoints in two Phase 1 clinical trials. The trials achieved the primary objectives by displaying the safety and immunogenicity of different doses of...
Clinical Trials
Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the start of a phase II clinical trial of oral inecalcitol in...
Clinical Trials
Millennium begins pharmacogenetics clinical outcomes study
Millennium Laboratories has commenced clinical outcomes study of its pharmacogenetic test. As part of the study, Millennium will evaluate the relationship between CYP genotype and clinical outcomes that include level of analgesia, functional status...
Clinical Trials
PhaseBio initiates Phase 2b trial of Glymera
PhaseBio Pharmaceuticals has commenced patient dosing in a multicenter Phase 2b trial designed to evaluate the efficacy and safety of three doses of once weekly Glymera compared to matched placebo as well as an active comparator for the...
Clinical Trials
Medistem announces initiation of critical limb ischemia study
Medistem and Shanghai Jia Fu Medical Apparatus have announced the initiation of critical limb ischemia study by treating first two patients with Endometrial Regenerative Cell (ERC) universal donor stem cells. No treatment-associated adverse events...
Clinical Trials
ImmunoGen begins Phase I cancer trial of IMGN853
ImmunoGen has announced the commencement of the Phase I trial of IMGN853 in ovarian cancer and other solid tumours over-expressing its folate receptor target, including non-small cell lung cancer. The multi-centre, first-in-human trial, will...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
